Warfarin and aspirin in patients with heart failure and sinus rhythm.

ABSTRACT:

Background

It is unknown whether warfarin or aspirin therapy is superior for patients with heart failure who are in sinus rhythm.

Methods

We designed this trial to determine whether warfarin (with a target international normalized ratio of 2.0 to 3.5) or aspirin (at a dose of 325 mg per day) is a better treatment for patients in sinus rhythm who have a reduced left ventricular ejection fraction (LVEF). We followed 2305 patients for up to 6 years (mean [±SD], 3.5±1.8). The primary outcome was the time to the first event in a composite end point of ischemic stroke, intracerebral hemorrhage, or death from any cause.

Results

The rates of the primary outcome were 7.47 events per 100 patient-years in the warfarin group and 7.93 in the aspirin group (hazard ratio with warfar

SUBMITTER: Homma S 

PROVIDER: S-EPMC3723382 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature